Sara Llufriu

About me

Featured publications

• Recommendations for the coordination of Neurology and Neuroradiology Departments in the management of patients with multiple sclerosis

  Authors: Llufriu S, Agüera E, Costa-Frossard L, Galán V, Landete L, Lourido D, Meca-Lallana JE, Moral E, Bravo-Rodríguez F, Koren L, Labiano A, León A, Martín P, Monedero MD, Requeni L, Zubizarreta I, Rovira À .

  Reference: Neurologia 2023.

• Diffusion tensor imaging metrics associated with future disability in multiple sclerosis

  Authors: Lopez-Soley E; Martinez-Heras E; Solana E; Solanes A; Radua J; Vivo F; Prados F; Sepulveda M; Cabrera-Maqueda JM; Fonseca E; Blanco Y; Alba-Arbalat S; Martinez-Lapiscina EH; Villoslada P; Saiz A; Llufriu S.

  Reference: Scientific Reports 2023.

• Preventing Neurodegeneration in Multiple Sclerosis Is Required From the Earliest Stages of the Disease

  Authors: Villoslada P; Llufriu S.

  Reference: Neurology 2022.

• Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders

  Authors: Guasp M, Rosa-Justicia M, Muñoz-Lopetegi A, Martínez-Hernández E, Armangué T, Sugranyes G, Stein H, Borràs R, Prades L, Ariño H, Planagumà J, De-La-Serna E, Escudero D, Llufriu S, Sánchez-Valle R, Santamaria J, Compte A, Castro-Fornieles J, Dalmau J, Spanish anti-NMDAR Encephalitis Study Group.

  Reference: Lancet Neurology 2022.

• Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis

  Authors: Lopez-Soley E, Martinez-Heras E, Andorra M, Solanes A, Radua J, Montejo C, Alba-Arbalat S, Sola-Valls N, Pulido-Valdeolivas I, Sepulveda M, Romero-Pinel L, Munteis E, Martínez-Rodríguez JE, Blanco Y, Martinez-Lapiscina EH, Villoslada P, Saiz A, Solana E, Llufriu S .

  Reference: J Pers Med 2021.

• Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability

  Authors: Capuano R, Zubizarreta I, Alba-Arbalat S, Sepulveda M, Sola-Valls N, Pulido-Valdeolivas I, Andorra M, Martinez-Heras E, Solana E, Lopez-Soley E, Montejo C, Blanco Y, Fernández-Velasco JI, Gallo A, Bisecco A, Villoslada P, Saiz A, Llufriu S, Villar LM, Martinez-Lapiscina EH .

  Reference: Multiple Sclerosis Journal 2021.

• Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients

  Authors: Solana E; Martinez-Heras E; Montal V; Vilaplana E; Lopez-Soley E; Radua J; Sola-Valls N; Montejo C; Blanco Y; Pulido-Valdeolivas I; Sepúlveda M; Andorra M; Berenguer J; Villoslada P; Martinez-Lapiscina EH; Prados F; Saiz A; Fortea J; Llufriu S.

  Reference: Scientific Reports 2021.

• Incidence and Impact of COVID-19 in MS: A Survey From a Barcelona MS Unit

  Authors: Sepúlveda M, Llufriu S, Martínez-Hernández E, Català M, Artola M, Hernando A, Montejo C, Pulido-Valdeolivas I, Martínez-Heras E, Guasp M, Solana E, Llansó L, Escudero D, Aldea M, Prats C, Graus F, Blanco Y, Saiz A .

  Reference: Neurology-Neuroimmunology & Neuroinflammation 2021.

• Characterization of multiple sclerosis lesions with distinct clinical correlates through quantitative diffusion MRI

  Authors: Martínez-Heras E; Solana E; Prados F; Andorrà M; Solanes A; López-Soley E; Montejo C; Pulido-Valdeolivas I; Alba-Arbalat S; Sola-Valls N; Sepúlveda M; Blanco Y; Saiz A; Radua J; Llufriu S.

  Reference: Neuroimage-Clinical 2020.

• Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial

  Authors: Zubizarreta I, Flórez-Grau G, Vila G, Cabezón R, España C, Andorra M, Saiz A, Llufriu S, Sepulveda M, Sola-Valls N, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Casanova B, Martinez Gines M, Tellez N, Oreja-Guevara C, Español M, Trias E, Cid J, Juan M, Lozano M, Blanco Y, Steinman L, Benitez-Ribas D, Villoslada P .

  Reference: Proceedings Of The National Academy Of Sciences Of The United States Of America 2019.

Featured Projects

• Neuroimaging multi-modal approach to understand mechanisms of tissue DAmage in Multiple sclerosis patients and predictive models (daMoS)

  Principal investigator: Sara Llufriu Duran

  Funder: Instituto de Salud Carlos III

  Code: PI21/01189

  Duration: 01/01/2022 - 31/12/2024

• Grup d'Imatge Avançada en Malalties Neuroimmunològiques (ImaginEM)

  Principal investigator: Sara Llufriu Duran

  Funder: Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR)

  Code: 2021-SGR-01325

  Duration: 01/01/2022 - 31/12/2024

• Rehabilitación cognitiva y plasticidad cerebral en la esclerosis múltiple: en búsqueda de la evidencia

  Principal investigator: Albert Saiz Hinarejos, Sara Llufriu Duran

  Funder: Instituto de Salud Carlos III FIS-ISCIII

  Code: PI18/01030

  Duration: 01/01/2019 - 31/12/2021

• Red española de esclerosis múltiple (REEM)

  Principal investigator: Sara Llufriu Duran

  Funder: Ministerio de Ciencia e Innovación ; IDIBAPS (August Pi i Sunyer Biomedical Research Institute), Barcelona, Spain (Sede o evento)

  Code: RD16/0015/0003

  Duration: 01/01/2017 - 31/12/2021

• Biomarcadores de resonancia magnética avanzada en esclerosis múltiple: asociación con el perfil clínico evolutivo y el sustrato genético

  Principal investigator: Albert Saiz Hinarejos, Sara Llufriu Duran

  Funder: Instituto de Salud Carlos III

  Code: PI15/00587

  Duration: 01/01/2016 - 30/11/2020